Results 111 to 120 of about 46,671 (223)

Latest Advances in the Treatment of Post-stroke Limb Spasm with Botulinum Neurotoxin

open access: yes, 2018
Objective: To describe the latest progress in the use of botulinum neurotoxin for post-stroke limb spasm. Methods: This paper looks up the relevant research literatures in recent years in PubMed, Web of Science, Springer, Ovid, CNKI, WanFang databases ...
Chen, Shuhua, Jin, Lingjing
core  

BOTULINUM NEUROTOXIN-CLINICAL USES

open access: yes, 2017
Introduction: Botulinum neurotoxin (BoNT) is produced by the spore-forming anaerobic bacterium Clostridium botulinum, which causes botulism. The symptoms of the disease are severe, expressed in tiredness, nausea and vomiting.
Tsankova, Dajana   +4 more
core   +1 more source

Characterization of a mosquitocidal botulinum toxin-like neurotoxin complex

open access: yes
reservedParaclostridial mosquitocidal protein 1 (PMP1), a botulinum-like toxin from Paraclostridium bifermentans, belongs to the clostridial neurotoxin (CNT) family, which includes botulinum and tetanus neurotoxins.
ANTONELLO, MARTA
core  

Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors

open access: yes, 2017
Botulinum neurotoxin B is a Food and Drug Administration-approved therapeutic toxin. However, it has lower binding affinity toward the human version of its major receptor, synaptotagmin II (h-Syt II), compared to mouse Syt II, because of a residue ...
Krupp, Johannes   +27 more
core   +1 more source

Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life

open access: yes, 2009
OBJECTIVE: To investigate the hypothesis that the need for clean intermittent self-catheterization after botulinum neurotoxin type A injections is outweighed by the efficacy of this treatment, so that clean intermittent self-catheterization is not a ...
Panicker, Jalesh   +5 more
core  

Botulinum neurotoxins

open access: yes, 2023
Botulinum neurotoxins (BoNTs) are the most potent toxins known to man, with less than 1 μg of pure toxin being enough to kill an adult man. Despite the high toxicity, BoNTs are widely used in cosmetics and in medicine for the treatment of an increasing number of medical conditions.
openaire   +1 more source

Camelid single-domain antibody ciA-B5 recognizes light chain of botulinum neurotoxin type A by ELISA

open access: yes
Camelid single-domain antibody (VHH) ciA-B5 detects by ELISA the light chain (LC) of the botulinum neurotoxin type A (BoNT/A)
Dang, Tran Nhat Minh   +8 more
core   +1 more source

Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm

open access: yesClinical Ophthalmology, 2011
Juwan Park1, Michael S Lee2, Andrew R Harrison31Department of Ophthalmology, The Catholic University of Korea, Seoul, Korea; 2Department of Ophthalmology, Neurology and Neurosurgery, 3Department of Ophthalmology and Otolaryngology, University of ...
Park J, Lee MS, Harrison AR
doaj  

TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids

open access: yes, 1986
The receptor structure of Clostridium botulinum neurotoxin type A was analysed by TLC immunostaining. GQ1b was found to be the most potent receptor, and the neurotoxin also bound to GT1b and GD1a, but not to GM3, GM2, GM1, GD3, GD1b and GT1a.
Kozaki, Shunji   +6 more
core   +1 more source

The Potential Therapeutic Effects of Botulinum Neurotoxins on Neoplastic Cells: A Comprehensive Review of In Vitro and In Vivo Studies

open access: yesToxins
A systematic review of the literature found fifteen articles on the effect of a botulinum toxin on neoplastic cell lines and eight articles on in vivo neoplasms.
Delaram Safarpour   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy